Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4437296 | 1.00 | GRIN2B (0.40) | GRIN2BGRIN2CJAK3USP2SMN1; SMN2 | |
| SCHEMBL4309286 | 1.00 | GRIN2B (0.40) | GRIN2BGRIN2CJAK3USP2SMN1; SMN2 | |
| SCHEMBL3554328 | 0.89 | GRIN2B (0.39) | GRIN2BGRIN2CJAK3USP2SMN1; SMN2 | |
| SCHEMBL2774828 | 0.84 | GRIN2B (0.41) | GRIN2BGRIN2CJAK3USP2SMN1; SMN2 | |
| SCHEMBL1268184 | 0.84 | GRIN2B (0.41) | GRIN2BGRIN2CJAK3USP2SMN1; SMN2 | |
| SCHEMBL199926 | 0.84 | GRIN2B (0.41) | GRIN2BGRIN2CJAK3USP2SMN1; SMN2 | |
| SCHEMBL5578431 | 0.84 | GRIN2B (0.38) | GRIN2BGRIN2CJAK3USP2SMN1; SMN2 | |
| SCHEMBL3000663 | 0.81 | GRIN2B (0.40) | GRIN2BGRIN2CJAK3USP2SMN1; SMN2 | |
| SCHEMBL3000664 | 0.81 | GRIN2B (0.40) | GRIN2BGRIN2CJAK3USP2SMN1; SMN2 | |
| SCHEMBL10039817 | 0.81 | GRIN2B (0.40) | GRIN2BGRIN2CJAK3USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2429568-B1 | MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARM INC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2422791-B1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8674088-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2316839-B1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS HAVING PHOSPHONATE GROUPS | GILEAD SCIENCES INC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-8586744-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8383583-B2 | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2043658-B1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2422791-A1 | Antiviral phosphinate compounds | Gilead Sciences, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-1778702-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2011-07-13 | — | — | EP | disclosed |
| EP-2316839-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20080267917-A1 | N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
| US-20080057031-A1 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008019266-A2 | ACYCLIC, PYRIDAZINONE-DERIVED HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| US-20080039375-A1 | Phosphorus-containing hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| WO-2008005565-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| EP-1539744-A4 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARM INC (US) | 2007-06-06 | — | — | EP | disclosed |
| US-20060122123-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2006-06-08 | — | — | US | disclosed |
| EP-1539744-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004007444-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080057031-A1 | Antiviral phosphinate compounds | PHOSPHO1, MAVS, ITPA | GRIN2B 2401/4885GRIN2C 1932/4885JAK3 1494/4885 |
| US-20080267917-A1 | N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, HPN, SPINT2 | GRIN2B 4502/4885GRIN2C 3968/4885JAK3 1783/4885 |
| US-20060122123-A1 | Antiviral compounds | EIF2AK2, MAVS, ITPA | GRIN2B 3278/4885GRIN2C 2994/4885JAK3 1129/4885 |
| US-20080039375-A1 | Phosphorus-containing hepatitis C serine protease inhibitors | PRSS1, PPP4C, G6PC1 | GRIN2B 4659/4885GRIN2C 4385/4885JAK3 1351/4885 |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | AMDHD2, OGA, ENGASE | GRIN2B 3167/4885GRIN2C 3498/4885JAK3 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.